Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Leticia Detrow didn’t have much of a choice. Her sprinting times had plateaued. And, unbeknownst to her, Randy Shank, her track coach at Maryland School for the Deaf, had signed her up for a pair of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of its minority ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

Patients with untreated advanced melanoma do not appear to gain a survival advantage from the addition of a cancer vaccine to pembrolizumab, suggests a trial.

"Under the SSA, Australian citizens who migrate to New Zealand, and meet the criteria for New Zealand benefits and pensions ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...